No Data
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Third Quarter Report 2024
Huiyu Pharmaceuticals (688553.SH) released its performance for the first three quarters, with a net income of 0.227 billion yuan, a year-on-year increase of 155.62%.
Huiyu Pharmaceutical (688553.SH) disclosed its third quarter report for 2024, achieving revenue of 8...
Huayu Pharmaceutical (688553.SH): The net income in the first three quarters was 0.227 billion yuan, a year-on-year increase of 155.62%.
Glory 10月25日丨Huiyu Pharmaceuticals (688553.SH) announced its third quarter report for 2024, with a company's revenue of 0.852 billion yuan in the first three quarters, a year-on-year increase of 29.24%; net income attributable to shareholders of the listed company was 0.227 billion yuan, a year-on-year increase of 155.62%; net profit attributable to shareholders of the listed company after deducting non-recurring losses was 0.1 billion yuan, a year-on-year increase of 141.81%; basic earnings per share was 0.54 yuan.
Huayu Pharmaceutical (688553.SH): The first subject in Phase I clinical trial of the biological innovative drug injection HY07121I was administered.
Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Huayu Haiyue Medical Technology Co., Ltd. in sichuan...
Huiyu Pharmaceutical (688553.SH): 18.3979 million shares of restricted stock will be unlocked on October 28th.
On October 18, Gelunhui announced that the total number of shares listed on Huoyu Pharmaceutical (688553.SH) this time is 18.3979 million shares. The date of stock listing is October 28, 2024. (Due to October 26, 2024 being a non-trading day, it is postponed to the next trading day).
Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?No Data
No Data
